Free Trial

Strata Wealth Advisors LLC Acquires Shares of 10,692 Pfizer Inc. $PFE

Pfizer logo with Medical background

Key Points

  • Strata Wealth Advisors LLC acquired 10,692 shares of Pfizer Inc. in Q2, valued at approximately $259,000, as the company continues to attract institutional investors.
  • Pfizer reported better-than-expected quarterly earnings with $0.78 EPS on a revenue of $14.65 billion, surpassing analyst estimates.
  • The company declared a quarterly dividend of $0.43 per share, which results in an annualized yield of 7.0%.
  • Interested in Pfizer? Here are five stocks we like better.

Strata Wealth Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,692 shares of the biopharmaceutical company's stock, valued at approximately $259,000.

Other hedge funds have also made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter worth $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.1%

NYSE PFE traded down $0.04 during mid-day trading on Thursday, reaching $24.69. 2,958,289 shares of the stock were exchanged, compared to its average volume of 46,572,949. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17. The business's fifty day simple moving average is $24.88 and its 200 day simple moving average is $24.13. The stock has a market capitalization of $140.35 billion, a PE ratio of 13.11, a PEG ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analysts Set New Price Targets

Several equities research analysts recently commented on PFE shares. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. UBS Group reiterated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Finally, Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of "Hold" and an average price target of $28.13.

Read Our Latest Stock Analysis on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Ways AI Is Creating Massive Profits — and the Stocks to Watch
Investors Are Bracing for a Crash — Here’s Where the Money’s Moving
Looking for Growth? This Tiny AI Stock Has MAJOR Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines